FY2024 EPS Estimates for Sarepta Therapeutics, Inc. Reduced by William Blair (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at William Blair lowered their FY2024 earnings estimates for shares of Sarepta Therapeutics in a report issued on Wednesday, May 1st. William Blair analyst T. Lugo now anticipates that the biotechnology company will earn $6.10 per share for the year, down from their previous estimate of $6.66. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

A number of other research firms have also weighed in on SRPT. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price for the company. UBS Group upped their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Barclays upped their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Royal Bank of Canada upped their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, Citigroup upped their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.60.

Sarepta Therapeutics Trading Up 1.0 %

Sarepta Therapeutics stock opened at $135.04 on Monday. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89. The firm’s 50 day moving average price is $125.63 and its 200-day moving average price is $110.74. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The stock has a market cap of $12.76 billion, a P/E ratio of 1,227.64 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter last year, the business posted ($1.44) earnings per share. The firm’s revenue was up 63.1% on a year-over-year basis.

Insiders Place Their Bets

In other news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Dallan Murray sold 3,635 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. Insiders have sold 25,731 shares of company stock worth $3,248,319 in the last three months. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Large investors have recently bought and sold shares of the stock. Howland Capital Management LLC purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at about $211,000. Riggs Asset Managment Co. Inc. lifted its stake in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Central Pacific Bank Trust Division acquired a new position in Sarepta Therapeutics during the first quarter valued at $414,000. Nordea Investment Management AB boosted its holdings in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares during the last quarter. Finally, Connecticut Wealth Management LLC acquired a new stake in Sarepta Therapeutics during the 1st quarter worth about $261,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.